Research programme: peptide-based therapeutics - Janssen Pharmaceuticals/PeptiDream

Drug Profile

Research programme: peptide-based therapeutics - Janssen Pharmaceuticals/PeptiDream

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PeptiDream
  • Developer Janssen Pharmaceuticals; PeptiDream
  • Class Drug conjugates; Macrocyclic compounds; Peptides; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 07 Apr 2017 Janssen Pharmaceuticals and PeptiDream entered into a licensing agreement for the development of peptide-based therapeutics for the treatment of metabolic and cardiovascular disorders
  • 07 Apr 2017 Early research in Cardiovascular disorders in Japan (unspecified route)
  • 07 Apr 2017 Early research in Metabolic disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top